Hypoparathyroidism
80
16
17
48
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
18 trials with published results (23%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.3%
5 terminated out of 80 trials
90.6%
+4.0% vs benchmark
21%
17 trials in Phase 3/4
38%
18 of 48 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 48 completed trials
Clinical Trials (80)
A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism
A Registry for Participants With Chronic Hypoparathyroidism
A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism
Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism
NIRAF-Guided Parathyroid Identification During Thyroidectomy
Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism
A Cohort Study on the Safety and Efficacy of XH-02 in Treating Hypoparathyroidism
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)
Efficacy and Safety of Subcutaneous Injection of XH-02 in the Treatment of Adult Hypoparathyroidism
Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism
Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
Parathyroid Allotransplant for Treatment of Hypoparathyroidism
Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo
Intraoperative Methylene Blue Spray for the Identification and Preservation of Vital Structures in Thyroidectomy
Palopegteriparatide in Chronic Hypoparathyroidism